Conclusions: Drotrecogin alfa (activated) - From bench to practical use at the bedside

American Journal of Surgery

Volumn 184, Issue 6 SUPPL. 1, 2002, Pages S47-S50

  Maki, Dennis G ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFECT; HUMAN; MORTALITY; MULTIPLE ORGAN FAILURE; PATIENT MONITORING; PATIENT SELECTION; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEPSIS; SEPTIC SHOCK; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036935265     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9610(02)01136-4     Document Type: Article

References (34)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States analysis of incidence, outcome, and associated costs of care . Crit Care Med. 29:2001;1303-1310.
2. Opal S.M., Cross A.S. Clinical trials for severe sepsis past failures and future hopes . Infect Dis Clin North Am. 13:1999;285-297.
3. Effect of high-dose glucocorticoid therapy on mortality in patients with signs of systemic sepsis. N Engl J Med. 317:1987;659-665.
4. Bone R.C., Fisher C.J. Jr, Clemmer T.P., et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 317:1987;653-658.
5. Angus D.C., Birmingham M.C., Balk R.A., et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis a randomized controlled trial. E5 Study Investigators . JAMA. 283:2000;1723-1730.
6. McCloskey R.V., Straube R.C., Sanders C., et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med. 121:1994;1-5.
7. Abraham E., Wunderink R., Silverman H., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter trial. TNF-alpha MAb Sepsis Study Group. JAMA. 273:1995;934-941.
8. Reinhart K., Karzai W. Anti-tumor necrosis factor therapy in sepsis update on clinical trials and lessons learned . Crit Care Med. 29:(suppl):2001;S121-S125.
9. Zeni F., Freeman B., Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock a reassessment . Crit Care Med. 25:1997;1095-1100.
10. Fourrier F., Chopin C., Goudemand J., et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 101:1992;816-823.
11. Fisher C.J., Yan S.B. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. 28:2000;S49-S56.
12. Mesters R.M., Helterbrand J., Utterback B.G., et al. Prognostic value of protein C levels in neutropenic patients at high risk of severe septic complications. Crit Care Med. 28:2000;2209-2216.
13. Yan S.B., Helterbrand J.D., Hartman D.L., et al. Low levels of protein C are associated with poor outcome in severe sepsis. Chest. 120:2001;915-922.
14. Esmon C.T. The protein C anticoagulant pathway. Arterioscler Thromb. 12:1992;135-145.
15. Esmon C.T. The protein C pathway. Crit Care Med. 28:2000;S44-S48.
16. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709.
17. Maki D.G., Kalil A.C., Basson B., Johnson G. III. Drotecogin alfa (activated) mortality benefit in patients with severe sepsis is unaffected by adequacy of antibiotic therapy the PROWESS experience [poster] . In: Abstracts and proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 27-30, 2002. 2002;L-375 American Society for Microbiology, San Diego, CA.
18. Dunham D. University of Wisconsin Hospital and Clinics guidelines for use of drotrecogin alfa (activated) (activated protein C, Xigris). UWHC Center for Drug Policy and Clinical Economics. Available at: http://pswi.org/communications/PDFs/Drotrecogin%20Alfa.pdf. Accessed September 25, 2002.
19. Gaydos L.A., Freireich E.J., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 266:1962;905-909.
20. Rinder H.M., Arbini A.A., Snyder E.L. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol. 6:1999;437-441.
21. Ibrahim E.H., Sherman G., Wad S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 118:2000;146-155.
22. Safdar N., Maki D.G. The commonality of risk factors for nosocomial colonization/ infection with antimicrobial-resistant Staphylococus aureus, Enterococcus, gram-negative bacilli, Clostridium difficile and Candida. Ann Intern Med. 136:2002;834-844.
23. Maki D.G. Management of life-threatening infection in the intensive care unit. Murray M.J., Coursin D.B., Pearl R.G., Prough D.S. Critical Care Medicine: Preoperative Management. 2nd ed. 2002;616-648 Lippincott Williams & Wilkins, Philadelphia. 50:
24. Jimenez M.F., Marshall J.C. Source control in the management of sepsis. Intensive Care Med. 27:(suppl 1):2001;S49-S62.
25. Balk R.A. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. Crit Care Clin. 16:2000;337-352.
26. Wheeler A.P., Bernard G.R. Treating patients with severe sepsis. N Engl J Med. 340:1999;207-214.
27. Schierhout G., Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients a systematic review of randomised trials . BMJ. 316:1998;961-964.
28. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 341:1999;403-409.
29. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 345:2001;1368-1377.
30. Packman M.I., Rackow E.C. Optimum left heart filling pressure during fluid resuscitation of patients with hypovolemic and septic shock. Crit Care Med. 11:1983;165-169.
31. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 340:1999;409-417.
32. Cerra F.B., Benitez M.R., Blackburn G.L., et al. Applied nutrition in ICU patients. A consensus statement of the American College of Chest Physicians. Chest. 111:1997;769-778.
33. Borum M.L., Lynn J., Zhong Z., et al. The effect of nutritional supplementation on survival in seriously ill hospitalized adults an evaluation of the SUPPORT data . J Am Geriatr Soc. 48:(5 suppl):2000;S33-S38.
34. Van den Berghe G., Woutors P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 345:2001;1368-1377.